Pipamazine
- Formerly used for morning sickness
administration
- None
- Withdrawn
- 1-[3-(2-chlorophenothiazin-10-yl)propyl]piperidine-4-carboxamide
- 84-04-8
- 6761
- 6503
- 653552FH1N
- D02606
- CHEBI:135641
- ChEMBL1909072
- DTXSID3023477
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
- InChI=1S/C21H24ClN3OS/c22-16-6-7-20-18(14-16)25(17-4-1-2-5-19(17)27-20)11-3-10-24-12-8-15(9-13-24)21(23)26/h1-2,4-7,14-15H,3,8-13H2,(H2,23,26)
- Key:OSJJYEUEJRVVOD-UHFFFAOYSA-N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Pipamazine (INN; trade names Mornidine, Mometine, Nausidol) is a drug of the phenothiazine class formerly used as an antiemetic. It is chemically related to chlorpromazine, but has negligible antipsychotic activity and produces few extrapyramidal side effects.[1]
Pipamazine was introduced to the U.S. market in 1959 by G. D. Searle & Company. It was advertised for morning sickness[2] and postoperative nausea and vomiting, and was claimed to reduce the need for postoperative analgesia.[3] It was eventually withdrawn from the U.S. market in 1969, after reports of hepatotoxicity (liver injury).[4][5]
There is very little published information on pipamazine; it is mostly absent from modern-day sources, apart from a few passing mentions in the pharmacological literature.[1]
Adverse effects
Mornidine advertisements for postoperative recovery claimed "unusually low side effects".[3] However, contemporary comparative trials found that hypotension (low blood pressure) was a substantial concern when the drug was given at normal dosages for this indication; blood pressure reductions of up to 70 mmHg were reported.[6] Reductions in dosage mitigated hypotension while maintaining antiemetic efficacy.
In his book The Creation of Psychopharmacology, Irish psychiatrist David Healy states that the failure of pipamazine to perform as a neuroleptic and its negative side effect profile helped Searle lose interest in the antipsychotic sector, and contributed to the company's refusal to market haloperidol in the United States.[7]
Synthesis
![](http://upload.wikimedia.org/wikipedia/commons/thumb/1/10/Pipamazine_synthesis.svg/500px-Pipamazine_synthesis.svg.png)
The alkylation of 2-chloro-10-(3-chloropropyl)phenothiazine [2765-59-5] (1) with Isonipecotamide [39546-32-2] (2) gives pipamazine (3).
References
- ^ a b Frota LH (2003). Cinqüenta anos de medicamentos antipsicóticos em psiquiatria (PDF) (in Portuguese) (1st ed.). Rio de Janeiro: UFRJ. p. 486. ISBN 85-903827-1-0. Archived from the original (PDF) on 2011-07-06. Retrieved 2010-09-28.
- ^ [No authors listed] (July 1959). "Now she can cook breakfast again..." (PDF). Canadian Medical Association Journal. 81 (1): 59. PMC 1830735. Advertisement.
- ^ a b [No authors listed] (April 1960). "Lessened postoperative vomiting with MORNIDINE" (PDF). Annals of Surgery. 151 (4). PMC 1613578. Advertisement.
- ^ 34 FR 12051. July 17, 1969.
- ^ Wysowski DK, Swartz L (June 2005). "Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions". Archives of Internal Medicine. 165 (12): 1363–9. doi:10.1001/archinte.165.12.1363. PMID 15983284.
- ^ Blatchford E (March 1961). "Studies of anti-emetic drugs: A comparative study of cyclizine (Marzine), pipamazine (Mornidine), trimethobenzamide (Tigan), and hyoscine". Canadian Journal of Anesthesia. 8 (2): 159–65. doi:10.1007/BF03021345.
- ^ Healy D (2002). "Explorations in a new world". The creation of psychopharmacology. Cambridge: Harvard University Press. pp. 123–4. ISBN 0-674-01599-1.
- ^ John W Cusic, Dr Henry William Sause, DE 1089386 (1960 to Searle & Co).
- ^ John W Cusic, Sause Henry William, U.S. patent 2,957,870 (1960 to Searle & Co).
- v
- t
- e
channel antagonists
receptor antagonists
(cannabinoids)
- Dronabinol
- Nabilone
- Tetrahydrocannabinol (cannabis)
(antihistamines)
(anticholinergics)
- Atropine
- Diphenhydramine
- Hydroxyzine (very mild)
- Hyoscyamine
- Scopolamine